Κυριακή 28 Νοεμβρίου 2021

Cochleovestibular involvement in patients with Fabry disease: data from the multicenter cohort FFABRY

xlomafota13 shared this article with you from Inoreader

Eur Arch Otorhinolaryngol. 2021 Nov 26. doi: 10.1007/s00405-021-07173-x. Online ahead of print.

ABSTRACT

PURPOSE: Fabry disease (FD) is a lysosomal storage disease responsible for cochleovestibular involvement. Exact prevalence and pathophysiological mechanisms behind ENT affections are still poorly known. Treating FD with enzyme replacement therapy (ERT) does not seem to significantly improve the ENT symptoms, while the impact of migalastat has yet to be determined.

METHODS: We carried out a retrospective multi-centre study on 47 patients from the FFABRY cohort who had an ENT consultation in the context of their FD. The information collected were as follows: clinical examination, videonystagmoscopy, pure-tone speech audiometry, videonystagmography or VHIT (Video Head Impulse Test). Severe hearing loss was defined as greater than 70 dB.

RESULTS: The median age of our cohort was 52 years with a non-negligible proportion of n on-classic variants and female carriers. 72.3% of the patients complained of at least one of the following symptoms: hearing loss, tinnitus or vertigo. Pure-tone audiometry was abnormal in 61.7% of the patients (29/47), while speech audiometry was abnormal for 41.7% of the patients. The age of the patients and hypertrophic cardiomyopathy were significantly associated with the existence of an anomaly in pure-tone audiometry results. Severe hearing loss (> 70 dB) was significantly more common in male patients.

DISCUSSION: Hearing loss is particularly frequent in FD and is not limited to classic phenotypes. Close ENT follow-up is essential for Fabry patients to detect those who might benefit from hearing aid. Further studies are needed to define the impact of migalastat on cochleovestibular symptoms.

PMID:34825971 | DOI:10.1007/s00405-021-07173-x

View on the web

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου